Document is current
Any future updates will be listed below
-
Authors
Burn, Edward https://orcid.org/0000-0002-9286-1128
Tebé, Cristian
Fernandez-Bertolin, Sergio
Aragon, Maria https://orcid.org/0000-0002-5990-6953
Recalde, Martina
Roel, Elena https://orcid.org/0000-0002-1964-3546
Prats-Uribe, Albert https://orcid.org/0000-0003-1202-9153
Prieto-Alhambra, Daniel https://orcid.org/0000-0002-3950-6346
Duarte-Salles, Talita
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (806968)
- License Information
-
More Information
Article History
Received: 11 August 2020
Accepted: 7 January 2021
First Online: 3 February 2021
Competing interests
: D.P.A. reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants. C.T. reports personal fees from Amgen, Boehringer ingelheim outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work. All other authors declare no competing interests.
